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heterogeneity, because it can be easily matched
with HER2 IHC slide under light microscope.
We agree to Arena et al. that detailed report of
HER2 IHC is the simplest way to report HER2
regional heterogeneity. As shown in our study,
heterogeneous HER2 expression was well matched
with HER2 regional or genetic heterogeneity.
The main issue pointed out by Chang is the
prognostic significance of HER2 intratumoral hetero-
geneity. He argued that the conflicting prognostic
effect of HER2 intratumoral heterogeneity is related
to patient treatment. We agree that different treat-
ment may account for different outcome, as shown in
the study by Bartlett et al.5 For survival analysis, they
used TEAM (Tamoxifen vs Exemestane adjuvant
Multicentre) pathology study composed of estrogen
receptor-positive early breast cancers, treated with
adjuvant endocrine therapy (exemestane versus
tamoxifen), but not with chemotherapy.6 However,
tumors with heterogeneous HER2 amplification
cannot be equated with those with borderline/low
HER2 amplification. Although HER2 genetic and
regional heterogeneity was more common in tumors
with equivocal/low-grade amplification, they were
found in 23 and 38% of tumors with equivocal/low-
grade amplification in our study. Thus, comparison
of our study with the HERA trial7 is not reasonable.
We admit that our study has a limitation for survival
analysis due to small number of heterogeneous cases.
Further large-scaled, well-designed studies will be
needed to find clinically relevant definition of HER2
intratumoral heterogeneity and to establish its
prognostic significance and predictive value for
HER2 targeted therapy.
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DDIT3, STT3A (ITM1), ARG2 and FAM129A (Niban, C1orf24) in
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To the editor: We have read with special interest,
the paper by Sigstad et al1 published in a recent
issue of Modern Pathology (25: 537-547, 2012).
The authors sought to confirm whether ITM1 (alias
STT3A), C1orf24 (aliases FAM129A and Niban),
DDIT3 (alias GADD153) and ARG2 could
discriminate follicular thyroid carcinoma (FTC)
from follicular thyroid adenoma (FTA). In their
study, they were not able to use these markers to
discriminate between FTC and FTA.
In our previous work we found that these markers
would discriminate between FTA and FTC with
high sensitivity and specificity. Custom antibodies
for ITM1 and C1orf24 and commercially available
ARG2 and DDIT3 antibodies were tested on thyroid
lesions commonly diagnosed as indeterminate
by fine-needle aspiration biopsy. We showed that
immunohistochemistry (IHC) was more sensitive
than quantitative PCR in detecting thyroid carcino-
mas, and that the combination of four markers was
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more effective than a single marker.2 Although
the antibody-based test had high sensitivity (1.0),
the specificity was lower (0.85). The false-positive
cases were Hu¨rthle cell adenomas (HCA), which
were positive for all four carcinoma markers.3 To
locate new HCA markers, in part to identify these
false positives, global gene expression profiling of a
HCA and a Hu¨rthle cell carcinoma was performed.
PVALB was identified as a new HCA marker, as it
was negative in a wide range of thyroid carcinomas
and was positive in HCA.4 This validation analysis
was consistent with our previous findings and also
demonstrated that C1orf24 is the best predictor
among the four carcinoma markers, followed by
ITM1.2
From the study by Sigstad et al1 it might
be concluded that there is no clinical utility for
these markers to distinguish between FTA and FTC.
We take this opportunity to call attention to some
variables that can influence test results and,
therefore, why these markers might be useful for
an important clinical problem and should be further
tested.
One important variable that may account for the
conflicting results is that different antibodies
for some of the genes were used. We used custom-
produced antibodies for ITM1 and C1orf24.
Moreover, Sigstad and coworkers’ antibodies were
generated using peptide conjugated to diphetheria
toxoid, whereas in our study the antibodies were
conjugated to keyhole limpet hemocyanin by the
lysine at the C-terminus. The selection of the carrier
protein and coupling strategy can greatly influence
the antibodies titer and specificity.
To check for specificity, it is important to use
appropriate controls, as well as the use of indepen-
dent methods. One appropriate first validation step
is overexpressing transfected cell lines compared
with control cells that lack the gene. To demonstrate
specific antibody binding, cells transfected with the
proteins of interest were our positive controls,
whereas parental cells were negative controls. The
predicted protein size was clearly observed in
originally C1orf24-free NIH3T3 cells that were
transfected with an expression vector containing
the cDNA of C1orf24. The protein was not detected
in normal thyroid tissues and parental cells. Inter-
estingly, a band of nearly 70 kDa was detected in an
FTC sample. Importantly, Adachi et al5 also
produced antibodies using C-terminal peptides
comparable to the one used by our group. The
protein was observed in NIH3T3 cells expressing
C1orf24 and human renal carcinoma cell lines,
whereas were not observed in normal kidney. The
authors suggested that the small size of C1orf24
protein may correspond to C1orf24 that have
undergone processing under stress conditions such
as oxidative stress and hypertonic stress.5
Sigstad et al1 showed that the polyclonal anti-
body against C1orf24 successfully identify the
expression of a 130 kDa protein in a follicular
carcinoma cell line (FTC 133) and a FTC sample.
However, the protein was also detected in 3/5 FTAs
and in two normal thyroids.1 We recently evaluated
its expression in a paired primary thyroid follicular
carcinoma (FTC 133) and lymph node metastatic
cell lines (FTC 236) and a FTC cell line (WRO). In
FTC 236 and WRO both the 130 and 70 kDa bands
were observed, whereas in FTC 133 cell line only a
70 kDa band was observed. These findings,
compared with the Sigstad et al,1 suggest that
different epitopes may have been recognized by
C1orf24 antibodies (data not shown).
Regarding the ITM1 antibody, the predicted size is
80 kDa. Sigstad et al1 detected a 60 kDa band in both
cell line and thyroid tissues. These findings suggest
the possibility that the ITM1 antibody employed in
their study and the one used in our study may have
detected different epitopes on the same protein or may
have recognized epitopes from different proteins.
Importantly, an antibody may work in a western
blot assay but fail in IHC. When the ultimate goal is
to use the antibody for IHC, the user must demon-
strate that the antibody is also able to specifically
identify its target on paraffin-embedded sections.
Although a negative control including no primary
antibody is valuable for the specificity of the
secondary antiserum, a negative control would be
a tissue that is known to not express the protein of
interest. Not only the expression of these markers
was absent in normal thyroid SAGE library but also
these proteins were negative in all IHC validation
steps.2 That is an important issue, as the presence of
cross-reactive substances in normal thyroid would
refute the diagnostic value of these markers because
fine-needle aspiration specimens will contain
normal thyroid cells. Hence, normal thyroid
should be included as negative control in all
validation steps. This concern should be better
addressed in the Sigstad et al1 study as nearly all
samples were positive for all antibodies. In their
study, it is not clear which sample and/or tissue was
used for the titration of the antibodies and used as
positive and negative control.
There were substantial differences between our
studies and the Sigstad study that may account for
different results. In addition to aforementioned
factors, variables such as the time before fixation,
the length of fixation time, differences in fixatives
and tissue processing can all affect tissue antigeni-
city and the status of the epitope of interest.
Furthermore, if the antibody has not been affinity
purified, it may produce a high background on
tissues. For instance, in our study we used affinity-
purified antibodies, reduced fixation time before
embedding in paraffin, reduced incubation period of
primary antibody and the peroxidase-quenching
step was performed using 100-fold higher concen-
tration. These variables may also explain their
inconsistent results, as when the authors used tissue
microarray samples purchased from US Biomax,
higher specificity and sensitivity was obtained.
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Sigstad et al1 conclusion, that this panel of
markers is not valid to distinguish FTA and FTC,
was also based on Matsumoto et al6 data. However,
in their manuscript, C1orf24 was expressed in
nearly all PTC and 50% of FTC, whereas was not
expressed in normal thyroid. Notably, we have also
emphasized that none of these markers should be
used alone.
We also share with other groups a strong belief
that C1orf24 has a role in the pathogenesis of other
tumor subtypes. Ito et al7 found that C1orf24 was
positive in 97% of head and neck squamous cell
carcinoma and in 66% of dysplastic lesion, whereas
was not observed in normal mucosal samples. It was
also identified as a new candidate marker for renal
carcinogenesis, as it was positive in sporadic human
renal carcinoma cell lines and not observed in
normal kidney.5 Finally, functional analyses have
supported that C1orf24 have a potential role in
protecting cells from genotoxic stress-induced
apoptosis.8 In addition, they demonstrated that
C1orf24 depletion increased cell apoptosis. The
authors suggest that AKT contributes to resistance
of cancer cells through C1orf24 phosphorylation—
promoted P53 degradation.8
It is clear that there is a need to perform more
studies using this panel of markers. A practical
challenge to demonstrate the clinical application of
our proposed antibody-based test is that we
had used custom-produced antibodies. Currently,
however, there are few companies that generated
antibodies against ITM1, C1orf24 and PVALB.
Unquestionably, a study designed to compare anti-
bodies of various sources, including all commer-
cially available and custom produced, should be
performed to determine antibodies specificity and
reproducibility and, therefore, whether they are
useful markers that can be applied into clinical
practice. However, one should have in mind that
one batch of an antibody may work, whereas the
next, with a different lot, may not. As antibody-
based test will be widely used on clinical decisions,
standardization and development of antibody guide-
lines are critical. For the meantime, if of our
responsibility to have our eyes open to all potential
problems and assure that the results are replicable
and likely to be correct.
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Reply to ‘The new molecular markers DDIT3, STT3A, ARG2 and
FAM129A are not useful in diagnosing thyroid follicular tumors’
Modern Pathology (2013) 26, 613–615; doi:10.1038/modpathol.2013.39
To the Editor: In reply to Carvalheira et al’s1 letter
regarding our article,2 we would like to answer as
follows:
First, considering the urgent need for markers to
distinguish between follicular adenoma (FTA) and
carcinoma (FTC) during FNA cytology, we find it
remarkable that no clinical studies have been
published validating the four classifiers originally
described by Cerutti et al.3 Indeed, we are unaware
of any diagnostic laboratory using these markers
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